Raymond James Financial Services Advisors, Inc. Apellis Pharmaceuticals, Inc. Transaction History
Raymond James Financial Services Advisors, Inc.
- $73.5 Billion
- Q3 2024
A detailed history of Raymond James Financial Services Advisors, Inc. transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Raymond James Financial Services Advisors, Inc. holds 15,494 shares of APLS stock, worth $445,917. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,494
Previous 14,446
7.25%
Holding current value
$445,917
Previous $554,000
19.49%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding APLS
# of Institutions
302Shares Held
112MCall Options Held
3.85MPut Options Held
1.09M-
Wellington Management Group LLP Boston, MA15.6MShares$448 Million0.08% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$342 Million14.88% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.1MShares$320 Million4.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.82MShares$282 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.8MShares$167 Million0.01% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $3.16B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...